CTOs on the Move

Axial Biotherapeutics

www.axialbiotherapeutics.com

 
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Axial Biotherapeutics raised $19.5M on 11/30/2016
Axial Biotherapeutics raised $25M on 02/27/2019

Similar Companies

Vytelle

With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.

Koronis Pharmaceuticals

Koronis Pharmaceuticals is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthego

Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego`s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.

Pneuma Respiratory

Founded in 2015, Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD. Pneuma is leveraging more than three decades of healthcare research and product development experience along with hand held device design and manufacturing expertise.

Recombinetics

Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.